$BAX

Baxter faces EU cancer drug shortage extending to Q1 2027 amid disappointing 2026 earnings guidance, projecting $1.85-$2.05 EPS versus $2.25 consensus.

Two closed-end funds offer high-yield income strategies: BlackRock Enhanced Equity Dividend Trust (BDJ) at 8.2% yield with 6% NAV discount, and PIMCO Corporate & Income Opportunity Fund (PTY) at 11.5% yield with 6.5% NAV premium.

Global IV solutions market projected to surge from $13.35B in 2025 to $29.47B by 2035, driven by rising chronic disease prevalence and critical care demand.

Global IV infusion pump market projected to grow from $6.72B in 2025 to $14.02B by 2035 at 7.6% CAGR, driven by aging populations and smart pump technology.

Blood plasma derivatives market to double to $104B by 2033, driven by rising disease prevalence and immunoglobulin demand across developed and emerging markets.

Hemostasis products market expected to grow from $1.94B to $3.28B by 2035, driven by increased surgeries and trauma cases requiring advanced bleeding control solutions.

Fibrin sealant market to double from $1.60B to $3.57B by 2035, driven by surgical demand and minimally invasive techniques despite accessibility challenges in developing regions.